(NASDAQ: AAPG) Ascentage Pharma Group International's forecast annual revenue growth rate of 235.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Ascentage Pharma Group International's revenue in 2026 is $54,401,532.On average, 10 Wall Street analysts forecast AAPG's revenue for 2026 to be $978,245,093,960, with the lowest AAPG revenue forecast at $624,010,784,160, and the highest AAPG revenue forecast at $1,196,718,668,280. On average, 10 Wall Street analysts forecast AAPG's revenue for 2027 to be $648,789,735,880, with the lowest AAPG revenue forecast at $352,140,313,880, and the highest AAPG revenue forecast at $1,107,025,843,040.
In 2028, AAPG is forecast to generate $718,589,599,880 in revenue, with the lowest revenue forecast at $413,564,194,200 and the highest revenue forecast at $886,458,272,800.